NC
RPRX icon

NinePointTwo Capital’s Royalty Pharma RPRX Stock Holding History

NinePointTwo Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,448
Closed -$232K – 317
2023
Q1 		$232K Hold
6,448
– – 0.09% 178
2022
Q4 		$254K Buy
+6,448
New +$269K 0.11% 61

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NinePointTwo Capital's RPRX Position: Q2 2023 in Review

NinePointTwo Capital sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 6,448 shares — an estimated $232K sold.

NinePointTwo Capital first reported a position in RPRX in Q4 2022 and held it in 2 quarters. The position peaked at $254K in Q4 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

  • NinePointTwo Capital reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 6,448 Royalty Pharma shares in Q2 2023, an estimated $232K.
  • NinePointTwo Capital first reported a position in Royalty Pharma in Q4 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Royalty Pharma position peaked at $254K in Q4 2022.
  • 325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.